


## Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) ~~The present invention relates to a variety of compounds which are useful according to the present invention. These compounds are~~ A method of treating glaucoma or lowering or controlling intraocular pressure in a subject comprising administering to the subject a compound represented by the following Formula A:



wherein R, R<sup>1</sup> and R<sup>2</sup> are independently chosen from hydrogen, C<sub>1-4</sub>alkyl;

R<sup>3</sup> is selected from hydrogen, C<sub>1-4</sub>alkyl, or R<sup>2</sup> and R<sup>3</sup> can complete a pyrrolidine or piperidine ring, which can be substituted with C<sub>1-4</sub>alkyl;

R<sup>4</sup> is hydrogen, halogen, C<sub>1-4</sub>alkyl;

R<sup>5</sup> and R<sup>6</sup> are independently chosen from hydrogen, halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylthio, C<sub>1-6</sub>alkylsulfonyl, C<sub>1-6</sub>alkylsulfoxide, nitrile, C<sub>1-6</sub>alkyl substituted with halogen;

R<sup>7</sup> is chosen from C=OR<sup>9</sup>; S(O)<sub>m</sub>R<sup>10</sup>; NR<sup>1</sup>-(C=O)-R<sup>11</sup>; C<sub>1-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, OC(=O)C<sub>1-8</sub>, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, C(=O)NR<sup>12</sup>R<sup>13</sup>, S(O)<sub>m</sub>NR<sup>12</sup>R<sup>13</sup>, NR<sup>14</sup>R<sup>15</sup>, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl, phenyl or pyridinyl; or R<sup>7</sup> can be chosen from a heterocyclic ring selected from an oxazole such as oxazol-2-yl, 4,5-dihydro-oxazol-2-yl, or benzoxazol-2-yl, an oxazine such as 5,6-dihydro-[1,3]oxazin-2-yl, a thiazole such as thiazol-2-yl, 4,5-dihydro-thiazol-2-yl, or benzothiazol-2-yl, an imidazole such as imidazol-2-yl, or imidazolidin-2-yl, [1,2,4]oxadiazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]thiadiazol-5-yl, or [1,2,4]thiadiazol-3-yl which

can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, phenyl or pyridinyl, or C<sub>1-6</sub>alkyl substituted with phenyl or pyridinyl;

but R<sup>7</sup> cannot be hydrogen, lower alkyl, hydroxyl, lower alkoxy, amino, mono- or di-loweralkyl amino, lower alkanoylamino, or halogen;

R<sup>8</sup> is selected from C<sub>1-6</sub>alkyl, phenyl which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, NR<sup>1</sup>(C=O)C<sub>1-6</sub>alkyl, or halogen;

R<sup>9</sup> is chosen from hydroxyl; C<sub>1-6</sub>alkoxy; C<sub>1-6</sub>alkoxy substituted with phenyl or pyridinyl which can be substituted with C<sub>1-4</sub>alkoxy or halogen; NR<sup>16</sup>R<sup>17</sup>; C<sub>1-6</sub>alkyl; or C<sub>1-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, NR<sup>12</sup>R<sup>13</sup>, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, S(O)<sub>m</sub>NR<sup>12</sup>R<sup>13</sup>, halogen, or phenyl or a heterocyclic ring selected from pyrrolidinyl, imidazolyl, morpholinyl, oxazolyl, isoxazolyl, thiazolyl, or tetrazolyl, or pyridinyl which can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl;

R<sup>10</sup> is chosen from NR<sup>12</sup>R<sup>13</sup>; C<sub>1-6</sub>alkyl; CH<sub>2</sub>phenyl or CH<sub>2</sub>pyridinyl which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, or haloC<sub>1-4</sub>alkyl; or C<sub>2-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, NR<sup>12</sup>R<sup>13</sup>, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, phenyl, pyridinyl or imidazolyl which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl;

R<sup>11</sup> is NH<sub>2</sub>; NR<sup>1</sup>R<sup>2</sup>; C<sub>1-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl;

R<sup>12</sup> and R<sup>13</sup> are independently selected from hydrogen; C<sub>1-6</sub>alkyl; CH<sub>2</sub>Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, or haloC<sub>1-4</sub>alkyl; C<sub>2-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, NR<sup>1</sup>COC<sub>1-6</sub>alkyl, or halogen; or R<sup>12</sup>, R<sup>13</sup>, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyl substituted with hydroxy, C<sub>1-4</sub>alkoxy or halogen;

R<sup>14</sup> and R<sup>15</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, hydroxyl, C<sub>1-6</sub>alkoxy, (C=O)-R<sup>11</sup>, S(O)<sub>m</sub>R<sup>8</sup>, phenyl or pyridinyl which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, or haloC<sub>1-4</sub>alkyl; or R<sup>14</sup>, R<sup>15</sup> and the nitrogen atom to which they are attached can form a heterocyclic ring selected from pyrrolidine, piperazine, or piperidine, which can be substituted with C<sub>1-6</sub>alkyl, phenyl, or pyridinyl;

**R<sup>16</sup>** and **R<sup>17</sup>** are independently selected from hydrogen; C<sub>1-6</sub>alkyl; hydroxyl; C<sub>1-6</sub>alkoxy; CH<sub>2</sub>Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, or haloC<sub>1-4</sub>alkyl; C<sub>2-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, halogen, NR<sup>1</sup>(C=O)C<sub>1-6</sub>alkyl, or a phenyl or a heterocyclic ring selected from a pyrrole, such as pyrrolidin-2-yl, an imidazole such as imidazo-2-yl or imidazo-4-yl, a morpholine such as morpholin-3-yl, a piperidine such as piperidin-4-yl, oxazolyl, isoxazolyl, thiazolyl, tetrazolyl, pyridinyl, which can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl, phenylC<sub>1-4</sub>alkyl, oxo (=O); or **R<sup>16</sup>**, **R<sup>17</sup>**, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyl substituted with hydroxy, oxo (=O), C<sub>1-4</sub>alkoxy, or phenyl;

**m** is 0 – 2;

**A** is N or CH; and

**X** and **Y** are either N or C, wherein **X** and **Y** cannot be the same; and the dashed bonds denote a suitably appointed single and double bond.

2. (original) The method of claim 1, wherein for the compound of Formula A:

**R**, **R<sup>1</sup>** and **R<sup>2</sup>** are independently chosen from hydrogen, C<sub>1-4</sub>alkyl;

**R<sup>3</sup>** is selected from hydrogen, C<sub>1-4</sub>alkyl, or **R<sup>2</sup>** and **R<sup>3</sup>** can complete a pyrrolidine or piperidine ring, which can be substituted with C<sub>1-4</sub>alkyl;

**R<sup>4</sup>** is hydrogen, C<sub>1-4</sub>alkyl;

**R<sup>5</sup>** and **R<sup>6</sup>** are independently chosen from hydrogen, halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylthio, C<sub>1-6</sub>alkylsulfonyl, C<sub>1-6</sub>alkylsulfoxide, nitrile, C<sub>1-6</sub>alkyl substituted with halogen;

**R<sup>7</sup>** is chosen from C=OR<sup>9</sup>; C<sub>1-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, OC(=O)C<sub>1-8</sub>, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, C(=O)NR<sup>12</sup>R<sup>13</sup>, S(O)<sub>m</sub>NR<sup>12</sup>R<sup>13</sup>, NR<sup>14</sup>R<sup>15</sup>, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl, phenyl or pyridinyl; or **R<sup>7</sup>** can be chosen from a heterocyclic ring selected from an oxazole such as oxazol-2-yl, 4,5-dihydro-oxazol-2-yl, or benzoxazol-2-yl, an oxazine such as 5,6-dihydro-[1,3]oxazin-2-yl, a thiazole such as thiazol-2-yl, 4,5-dihydro-thiazol-2-yl, or benzothiazol-2-yl, an imidazole such as imidazol-2-yl, or imidazolidin-2-yl, [1,2,4]oxadiazol-5-yl,

[1,2,4]oxadiazol-3-yl, [1,2,4]thiadiazol-5-yl, or [1,2,4]thiadiazol-3-yl which can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, phenyl or pyridinyl, or C<sub>1-6</sub>alkyl substituted with phenyl or pyridinyl;

but R<sup>7</sup> cannot be hydrogen, lower alkyl, hydroxyl, lower alkoxy, amino, mono- or di-loweralkyl amino, lower alkanoylamino, or halogen;

R<sup>8</sup> is selected from C<sub>1-6</sub>alkyl, phenyl which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, NR<sup>1</sup>(C=O)C<sub>1-6</sub>alkyl, or halogen;

R<sup>9</sup> is chosen from hydroxyl; C<sub>1-6</sub>alkoxy; C<sub>1-6</sub>alkoxy substituted with phenyl or pyridinyl which can be substituted with C<sub>1-4</sub>alkoxy or halogen; NR<sup>16</sup>R<sup>17</sup>; C<sub>1-6</sub>alkyl; or C<sub>1-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, NR<sup>12</sup>R<sup>13</sup>, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, S(O)<sub>m</sub>NR<sup>12</sup>R<sup>13</sup>, halogen, or phenyl or a heterocyclic ring selected from pyrrolidinyl, imidazolyl, morpholinyl, oxazolyl, isoxazolyl, thiazolyl, or tetrazolyl, or pyridinyl which can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl;

R<sup>11</sup> is NH<sub>2</sub>; NR<sup>1</sup>R<sup>2</sup>; C<sub>1-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl;

R<sup>12</sup> and R<sup>13</sup> are independently selected from hydrogen; C<sub>1-6</sub>alkyl; CH<sub>2</sub>Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, or haloC<sub>1-4</sub>alkyl; C<sub>2-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, NR<sup>1</sup>COC<sub>1-6</sub>alkyl, or halogen; or R<sup>12</sup>, R<sup>13</sup>, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyl substituted with hydroxy, C<sub>1-4</sub>alkoxy or halogen;

R<sup>14</sup> and R<sup>15</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, hydroxyl, C<sub>1-6</sub>alkoxy, (C=O)-R<sup>11</sup>, S(O)<sub>m</sub>R<sup>8</sup>, phenyl or pyridinyl which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, or haloC<sub>1-4</sub>alkyl; or R<sup>14</sup>, R<sup>15</sup> and the nitrogen atom to which they are attached can form a heterocyclic ring selected from pyrrolidine, piperazine, or piperidine, which can be substituted with C<sub>1-6</sub>alkyl, phenyl, or pyridinyl;

R<sup>16</sup> and R<sup>17</sup> are independently selected from hydrogen; C<sub>1-6</sub>alkyl; hydroxyl; C<sub>1-6</sub>alkoxy; CH<sub>2</sub>Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, or haloC<sub>1-4</sub>alkyl;

C<sub>2-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, halogen, NR<sup>1</sup>(C=O)C<sub>1-6</sub>alkyl, or a phenyl or a heterocyclic ring selected from a pyrrole, such as pyrrolidin-2-yl, an imidazole such as imidazo-2-yl or imidazo-4-yl, a morpholine such as morpholin-3-yl, a piperidine such as piperidin-4-yl, oxazolyl, isoxazolyl, thiazolyl, tetrazolyl, pyridinyl, which can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl, phenylC<sub>1-4</sub>alkyl, oxo (=O); or R<sup>16</sup>, R<sup>17</sup>, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyl substituted with hydroxy, oxo (=O), C<sub>1-4</sub>alkoxy, or phenyl;

**m** is 0 – 2;

**A** is N; and

**X** and **Y** are either N or C, wherein X and Y cannot be the same; and the dashed bonds denote a suitably appointed single and double bond.

3. (original) The method of claim 2, wherein the compound of Formula A is:

1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid amide;


1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid methyl amide fumarate;

1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (1-hydroxy-cyclopropylmethyl)-amide; or

1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide.

4. (original) The method of claim 3, wherein the compound of Formula A is 1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide.

5. (original) A compound of Formula A:



**A**

wherein **R**, **R**<sup>1</sup> and **R**<sup>2</sup> are independently chosen from hydrogen, C<sub>1-4</sub>alkyl;

**R**<sup>3</sup> is selected from hydrogen, C<sub>1-4</sub>alkyl, or **R**<sup>2</sup> and **R**<sup>3</sup> can complete a pyrrolidine or piperidine ring, which can be substituted with C<sub>1-4</sub>alkyl;

**R**<sup>4</sup> is hydrogen, halogen, C<sub>1-4</sub>alkyl;

**R**<sup>5</sup> and **R**<sup>6</sup> are independently chosen from hydrogen, halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylthio, C<sub>1-6</sub>alkylsulfonyl, C<sub>1-6</sub>alkylsulfoxide, nitrile, C<sub>1-6</sub>alkyl substituted with halogen;

**R**<sup>7</sup> is chosen from C=OR<sup>9</sup>; S(O)<sub>m</sub>R<sup>10</sup>; NR<sup>1</sup>-(C=O)-R<sup>11</sup>; C<sub>1-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, OC(=O)C<sub>1-8</sub>, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, C(=O)NR<sup>12</sup>R<sup>13</sup>, S(O)<sub>m</sub>NR<sup>12</sup>R<sup>13</sup>, NR<sup>14</sup>R<sup>15</sup>, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl, phenyl or pyridinyl; or **R**<sup>7</sup> can be chosen from a heterocyclic ring selected from an oxazole such as oxazol-2-yl, 4,5-dihydro-oxazol-2-yl, or benzoxazol-2-yl, an oxazine such as 5,6-dihydro-[1,3]oxazin-2-yl, a thiazole such as thiazol-2-yl, 4,5-dihydro-thiazol-2-yl, or benzothiazol-2-yl, an imidazole such as imidazol-2-yl, or imidazolidin-2-yl, [1,2,4]oxadiazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]thiadiazol-5-yl, or [1,2,4]thiadiazol-3-yl which can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, phenyl or pyridinyl, or C<sub>1-6</sub>alkyl substituted with phenyl or pyridinyl;

but **R**<sup>7</sup> cannot be hydrogen, lower alkyl, hydroxyl, lower alkoxy, amino, mono- or di-loweralkyl amino, lower alkanoylamino, or halogen;

**R**<sup>8</sup> is selected from C<sub>1-6</sub>alkyl, phenyl which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, NR<sup>1</sup>(C=O)C<sub>1-6</sub>alkyl, or halogen;

**R**<sup>9</sup> is chosen from hydroxyl; C<sub>1-6</sub>alkoxy; C<sub>1-6</sub>alkoxy substituted with phenyl or pyridinyl which can be substituted with C<sub>1-4</sub>alkoxy or halogen; NR<sup>16</sup>R<sup>17</sup>; C<sub>1-6</sub>alkyl; or C<sub>1-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, NR<sup>12</sup>R<sup>13</sup>, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, S(O)<sub>m</sub>NR<sup>12</sup>R<sup>13</sup>, halogen, or phenyl or a heterocyclic ring selected from pyrrolidinyl, imidazolyl, morpholinyl, oxazolyl, isoxazolyl, thiazolyl, or tetrazolyl, or pyridinyl which can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl;

$R^{10}$  is chosen from  $NR^{12}R^{13}$ ;  $C_{1-6}$ alkyl;  $CH_2$ phenyl or  $CH_2$ pyridinyl which can be substituted with  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halogen, or halo $C_{1-4}$ alkyl; or  $C_{2-6}$ alkyl substituted with hydroxyl,  $C_{1-6}$ alkoxy,  $NR^{12}R^{13}$ ,  $CO_2H$ ,  $CO_2C_{1-6}$ alkyl, phenyl, pyridinyl or imidazolyl which can be substituted with  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halogen, halo $C_{1-4}$ alkyl;

$R^{11}$  is  $NH_2$ ;  $NR^1R^2$ ;  $C_{1-6}$ alkyl substituted with hydroxyl,  $C_{1-6}$ alkoxy,  $CO_2H$ ,  $CO_2C_{1-6}$ alkyl, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halogen, halo $C_{1-4}$ alkyl;

$R^{12}$  and  $R^{13}$  are independently selected from hydrogen;  $C_{1-6}$ alkyl;  $CH_2Z$ , where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halogen, or halo $C_{1-4}$ alkyl;  $C_{2-6}$ alkyl substituted with hydroxyl,  $C_{1-6}$ alkoxy,  $CO_2H$ ,  $CO_2C_{1-6}$ alkyl,  $NR^1COC_{1-6}$ alkyl, or halogen; or  $R^{12}$ ,  $R^{13}$ , and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with  $C_{1-4}$ alkyl or  $C_{1-4}$ alkyl substituted with hydroxy,  $C_{1-4}$ alkoxy or halogen;

$R^{14}$  and  $R^{15}$  are independently selected from hydrogen,  $C_{1-6}$ alkyl, hydroxyl,  $C_{1-6}$ alkoxy,  $(C=O)-R^{11}$ ,  $S(O)_mR^8$ , phenyl or pyridinyl which can be substituted with  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halogen, or halo $C_{1-4}$ alkyl; or  $R^{14}$ ,  $R^{15}$  and the nitrogen atom to which they are attached can form a heterocyclic ring selected from pyrrolidine, piperazine, or piperidine, which can be substituted with  $C_{1-6}$ alkyl, phenyl, or pyridinyl;

$R^{16}$  and  $R^{17}$  are independently selected from hydrogen;  $C_{1-6}$ alkyl; hydroxyl;  $C_{1-6}$ alkoxy;  $CH_2Z$ , where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halogen, or halo $C_{1-4}$ alkyl;  $C_{2-6}$ alkyl substituted with hydroxyl,  $C_{1-6}$ alkoxy, halogen,  $NR^1(C=O)C_{1-6}$ alkyl, or a phenyl or a heterocyclic ring selected from a pyrrole, such as pyrrolidin-2-yl, an imidazole such as imidazo-2-yl or imidazo-4-yl, a morpholine such as morpholin-3-yl, a piperidine such as piperidin-4-yl, oxazolyl, isoxazolyl, thiazolyl, tetrazolyl, pyridinyl, which can be unsubstituted or substituted with  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halogen, halo $C_{1-4}$ alkyl, phenyl $C_{1-4}$ alkyl, oxo ( $=O$ ); or  $R^{16}$ ,  $R^{17}$ , and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with  $C_{1-4}$ alkyl or  $C_{1-4}$ alkyl substituted with hydroxy, oxo ( $=O$ ),  $C_{1-4}$ alkoxy, or phenyl;

**m** is 0 – 2;

**A** is N or CH; and

**X** and **Y** are either N or C, wherein **X** and **Y** cannot be the same; and the dashed bonds denote a suitably appointed single and double bond.

6. (original) The compound of claim 5, wherein for Formula A:

wherein **R**, **R**<sup>1</sup> and **R**<sup>2</sup> are independently chosen from hydrogen, C<sub>1-4</sub>alkyl;

**R**<sup>3</sup> is selected from hydrogen, C<sub>1-4</sub>alkyl, or **R**<sup>2</sup> and **R**<sup>3</sup> can complete a pyrrolidine or piperidine ring, which can be substituted with C<sub>1-4</sub>alkyl;

**R**<sup>4</sup> is hydrogen, C<sub>1-4</sub>alkyl;

**R**<sup>5</sup> and **R**<sup>6</sup> are independently chosen from hydrogen, halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylthio, C<sub>1-6</sub>alkylsulfonyl, C<sub>1-6</sub>alkylsulfoxide, nitrile, C<sub>1-6</sub>alkyl substituted with halogen;

**R**<sup>7</sup> is chosen from C=OR<sup>9</sup>; C<sub>1-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, OC(=O)C<sub>1-8</sub>, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, C(=O)NR<sup>12</sup>R<sup>13</sup>, S(O)<sub>m</sub>NR<sup>12</sup>R<sup>13</sup>, NR<sup>14</sup>R<sup>15</sup>, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl, phenyl or pyridinyl; or **R**<sup>7</sup> can be chosen from a heterocyclic ring selected from an oxazole such as oxazol-2-yl, 4,5-dihydro-oxazol-2-yl, or benzoxazol-2-yl, an oxazine such as 5,6-dihydro-[1,3]oxazin-2-yl, a thiazole such as thiazol-2-yl, 4,5-dihydro-thiazol-2-yl, or benzothiazol-2-yl, an imidazole such as imidazol-2-yl, or imidazolidin-2-yl, [1,2,4]oxadiazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]thiadiazol-5-yl, or [1,2,4]thiadiazol-3-yl which can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, phenyl or pyridinyl, or C<sub>1-6</sub>alkyl substituted with phenyl or pyridinyl;

but **R**<sup>7</sup> cannot be hydrogen, lower alkyl, hydroxyl, lower alkoxy, amino, mono- or di-loweralkyl amino, lower alkanoylamino, or halogen;

**R**<sup>8</sup> is selected from C<sub>1-6</sub>alkyl, phenyl which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, NR<sup>1</sup>(C=O)C<sub>1-6</sub>alkyl, or halogen;

**R**<sup>9</sup> is chosen from hydroxyl; C<sub>1-6</sub>alkoxy; C<sub>1-6</sub>alkoxy substituted with phenyl or pyridinyl which can be substituted with C<sub>1-4</sub>alkoxy or halogen; NR<sup>16</sup>R<sup>17</sup>; C<sub>1-6</sub>alkyl; or C<sub>1-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, NR<sup>12</sup>R<sup>13</sup>, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, S(O)<sub>m</sub>NR<sup>12</sup>R<sup>13</sup>, halogen, or phenyl or a heterocyclic ring selected from pyrrolidinyl, imidazolyl, morpholinyl, oxazolyl, isoxazolyl,



thiazolyl, or tetrazolyl, or pyridinyl which can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl;

**R**<sup>11</sup> is NH<sub>2</sub>; NR<sup>1</sup>R<sup>2</sup>; C<sub>1-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl;

**R**<sup>12</sup> and **R**<sup>13</sup> are independently selected from hydrogen; C<sub>1-6</sub>alkyl; CH<sub>2</sub>Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, or haloC<sub>1-4</sub>alkyl; C<sub>2-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, NR<sup>1</sup>COC<sub>1-6</sub>alkyl, or halogen; or **R**<sup>12</sup>, **R**<sup>13</sup>, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyl substituted with hydroxy, C<sub>1-4</sub>alkoxy or halogen;

**R**<sup>14</sup> and **R**<sup>15</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, hydroxyl, C<sub>1-6</sub>alkoxy, (C=O)-R<sup>11</sup>, S(O)<sub>m</sub>R<sup>8</sup>, phenyl or pyridinyl which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, or haloC<sub>1-4</sub>alkyl; or **R**<sup>14</sup>, **R**<sup>15</sup> and the nitrogen atom to which they are attached can form a heterocyclic ring selected from pyrrolidine, piperazine, or piperidine, which can be substituted with C<sub>1-6</sub>alkyl, phenyl, or pyridinyl;

**R**<sup>16</sup> and **R**<sup>17</sup> are independently selected from hydrogen; C<sub>1-6</sub>alkyl; hydroxyl; C<sub>1-6</sub>alkoxy; CH<sub>2</sub>Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, or haloC<sub>1-4</sub>alkyl; C<sub>2-6</sub>alkyl substituted with hydroxyl, C<sub>1-6</sub>alkoxy, halogen, NR<sup>1</sup>(C=O)C<sub>1-6</sub>alkyl, or a phenyl or a heterocyclic ring selected from a pyrrole, such as pyrrolidin-2-yl, an imidazole such as imidazo-2-yl or imidazo-4-yl, a morpholine such as morpholin-3-yl, a piperidine such as piperidin-4-yl, oxazolyl, isoxazolyl, thiazolyl, tetrazolyl, pyridinyl, which can be unsubstituted or substituted with C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halogen, haloC<sub>1-4</sub>alkyl, phenylC<sub>1-4</sub>alkyl, oxo (=O); or **R**<sup>16</sup>, **R**<sup>17</sup>, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkyl substituted with hydroxy, oxo (=O), C<sub>1-4</sub>alkoxy, or phenyl;

**m** is 0 – 2;

**A** is N; and

X and Y are either N or C, wherein X and Y cannot be the same; and the dashed bonds denote a suitably appointed single and double bond.

7. (original) The compound of claim 6, wherein for Formula A: R<sup>7</sup> is not a substituted C<sub>1-6</sub> alkyl.

8. (original) The compound of claim 7, wherein the compound is:

1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid amide;

1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid methyl amide fumarate;

1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (1-hydroxy-cyclopropylmethyl)-amide; or

1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide.

9. (original) The compound of claim 8, wherein the compound is 1-((S)-2-Aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide.